What Are Cannabis ETFs?
Cannabis ETFs provide diversified exposure to the legal marijuana industry, including cannabis growers, distributors, biotech companies developing cannabis-derived medicines, and ancillary businesses that supply the industry with equipment, packaging, and technology. These funds allow investors to participate in the emerging cannabis market without picking individual companies in an extremely volatile sector.
The cannabis industry operates in a unique regulatory environment. While many U.S. states and Canada have legalized marijuana, it remains a Schedule I substance under U.S. federal law. This regulatory patchwork creates both challenges and opportunities. Cannabis ETFs attempt to navigate this complexity by providing diversified exposure across the industry's many players.
Cannabis ETFs rank among the most speculative sector funds available. The industry is young, many companies are unprofitable, and regulatory outcomes remain uncertain. Investors should understand these risks thoroughly before allocating capital.
Top Cannabis ETFs Compared
MSOS — AdvisorShares Pure US Cannabis ETF
MSOS is the most popular U.S.-focused cannabis ETF, holding multi-state operators (MSOs) through total return swap agreements that navigate the legal complexities of U.S. cannabis companies not being able to list on major exchanges. Top holdings include Curaleaf, Green Thumb Industries, and Trulieve. MSOS charges 0.78% and provides the most direct exposure to U.S. cannabis operations.
MJ — ETFMG Alternative Harvest ETF
MJ takes a broader global approach, holding both Canadian licensed producers and international cannabis companies. It also includes tobacco and pharmaceutical companies with cannabis interests. MJ charges 0.75% and provides more diversified but less pure cannabis exposure than MSOS. Canadian producers like Tilray and Canopy Growth feature prominently.
Why Cannabis ETFs Have Struggled
Cannabis ETFs experienced a dramatic boom-and-bust cycle. In 2020-2021, optimism about federal legalization and booming state-level sales drove cannabis stocks to extreme valuations. MSOS surged over 100% from late 2020 into early 2021 as investors anticipated sweeping federal reform under a new administration.
The bust was severe. Federal legalization stalled in Congress. Canadian producers suffered from oversupply and plummeting wholesale prices. Many U.S. operators burned through cash and struggled to achieve profitability. By 2023, MSOS had lost roughly 80% from its peak. The sector illustrated the classic danger of investing in hope and hype rather than fundamentals.
Structural challenges persist. The federal prohibition limits U.S. operators' access to banking services, prevents them from listing on major exchanges, and imposes punitive tax treatment under IRC Section 280E. Until federal reform addresses these obstacles, the industry faces headwinds that cannabis ETFs cannot avoid.
The Federal Legalization Catalyst
Federal legalization or rescheduling is the single biggest potential catalyst for cannabis ETFs. The DEA's movement toward rescheduling marijuana from Schedule I to Schedule III would have immediate, tangible benefits: elimination of 280E tax penalties (saving operators millions), easier access to banking services, and potential eligibility for major exchange listings.
Full legalization would go further, opening interstate commerce, allowing institutional investment, and dramatically expanding the addressable market. Most cannabis ETF investors are essentially making a bet on the timing and extent of federal reform — it is the defining investment thesis for the sector.
However, federal action has been slower than advocates expected. Multiple reform bills have stalled in Congress. Investors who bought cannabis ETFs expecting imminent legalization have been punished by years of delays. Any cannabis allocation should be sized with the understanding that reform timelines are unpredictable.
Risks of Cannabis ETFs
Regulatory uncertainty: Federal prohibition creates legal complexity and limits growth. State-by-state legalization progresses slowly and unevenly.
Profitability challenges: Many cannabis companies have never been profitable. High tax rates, compliance costs, and pricing pressure make profitability difficult to achieve.
Dilution: Cannabis companies frequently raise capital by issuing new shares, diluting existing shareholders. This is especially common among Canadian licensed producers.
Illiquidity: U.S. cannabis stocks trade on over-the-counter markets rather than major exchanges, resulting in wider bid-ask spreads and less institutional ownership.
Cannabis ETFs should represent only a speculative slice of a diversified portfolio — typically no more than 2-3% for investors who believe in the long-term legalization thesis. Compare them alongside less volatile sector ETFs to maintain portfolio balance.
